Hypertension is one of the common diseases in the elderly. The prevalence of hypertension markedly increases with advancing age. Both aging and hypertension have a critical role in cardiovascular and cerebrovascular complications. Although aging and hypertension, either independently or collectively, impair endothelial function, aging and hypertension may have similar cascades for the pathogenesis and development of endothelial dysfunction. Nitric oxide (NO) has an important role in regulation of vascular tone. Decrease in NO bioavailability by endothelial dysfunction would lead to elevation of blood pressure. An imbalance of reduced production of NO or increased production of reactive oxygen species, mainly superoxide, may promote endothelial dysfunction. One possible mechanism by which the prevalence of hypertension is increased in relation to aging may be advancing endothelial dysfunction associated with aging through an increase in oxidative stress. In addition, endothelial cell senescence is also involved in aging-related endothelial dysfunction. In this review, we focus on recent findings and interactions between endothelial function, oxidative stress and hypertension in aging.
INTRODUCTION
Hypertension causes fatal cardiovascular diseases as a silent killer. It is well known that hypertension is one of the common diseases in the elderly. The prevalence of hypertension markedly increases with advancing age. Both aging and hypertension are independent predictors of cardiovascular and cerebrovascular outcomes. 1,2 Aging is associated with alterations of vascular structure and function through various pathways, including oxidative stress, cell senescence and inflammation. [3] [4] [5] In addition, the presence of hypertension accelerates aging-related alterations of vascular structure and function, particularly endothelial function. 6, 7 Endothelial dysfunction is an early feature of atherosclerosis and vascular diseases in humans. 8 A great number of studies have shown that aging and hypertension are associated with impairment of endothelium-dependent vascular relaxation in coronary, forearm and renal arteries, and endothelial dysfunction, which is involved in the development of atherosclerosis, was found to increase the risk of cardiovascular and cerebrovascular diseases. [9] [10] [11] [12] [13] [14] [15] [16] [17] It is expected that improvement or augmentation of endothelial function will prevent the development of atherosclerosis, resulting in reduction in cardiovascular and cerebrovascular events.
Several possible mechanisms by which advanced aging and hypertension impair endothelial function have been postulated. An imbalance of reduced production of nitric oxide (NO) or increased production of reactive oxygen species (ROS), mainly superoxide, may promote endothelial dysfunction. [18] [19] [20] The key mechanism by which endothelium-dependent vasodilation is impaired is an increase in oxidative stress that inactivates NO. When considering aging-related endothelial dysfunction, the role of endothelial cell senescence in endothelial dysfunction should also be discussed.
In this review, we focus on recent findings and putative mechanisms by which aging, aging-associated hypertension and hypertension per se, either independently or collectively impair endothelial function.
ENDOTHELIAL FUNCTION
Until 1981, it was thought that the vascular endothelium functions as a wall separating the vessel wall and the inside cavity. If the endothelium of the whole body can be collected, its total weight would be equal to the liver, its total area would be equal to six tennis courts and its total length would be equal to two and half times around the globe, 100 000 km (Figure 1) . 21 In addition, it is well known that the endothelium secretes various vasoactive agents, such as the vasodilators NO, prostacyclin and endothelium-derived hyperpolarizing factor and the vasoconstrictors, such as endothelin-1, angiotensin II (Ang II) and thromboxane A 2 . [22] [23] [24] [25] It is concluded that the endothelium is the biggest endocrine organ in the human body. A healthy endothelium maintains vascular tone and structure by regulating the balance between vasodilation and vasoconstriction, growth inhibition and growth promotion, antithrombosis and prothrombosis, anti-inflammation and proinflammation, and also antioxidation and pro-oxidation. [23] [24] [25] [26] The simple molecule NO regulates basal vascular tone, at least in part, by about 50% in the brachial artery in humans. 11, 26 Thus, loss of healthy endothelial function becomes a trigger of atherosclerosis. Endothelial dysfunction is the initial step in the pathogenesis of arteriosclerosis, resulting in cardiovascular complications. 8 Indeed, the cumulative cardiovascular event rates in hypertensive patients with high-grade endothelial dysfunction were higher than in hypertensive patients with lowgrade endothelial dysfunction. 27 These findings suggest that forearm endothelial dysfunction is a prediction of future cardiovascular events in patients with hypertension. Lerman and Zeiher 28 reported the results of multivariant analysis of hazard ratios of studies showing an association between coronary or peripheral endothelial function and cardiovascular events. In cardiovascular diseases other than hypertension, endothelial dysfunction is strongly and independently associated with cardiovascular events. 29, 30 Hypertension, diabetes mellitus, dyslipidemia, aging, smoking, obesity and menopause are contributing risk factors in cardiovascular and cerebrovascular disease. These diseases and classical cardiovascular risk factors are associated with endothelial dysfunction. It is thought that endothelial function is a therapeutic target for atherosclerosis. Endothelial function is restored by appropriate interventions, including pharmacological therapy, such as renin-angiotensin system inhibitors and statins, supplementation therapy and lifestyle modifications. 11, [31] [32] [33] [34] [35] ASSESSMENT OF ENDOTHELIAL FUNCTION In experimental studies, methods for assessment of endothelial function have been established by using a ring experiment protocol, endothelial functional alteration in expression of transcriptional factors and genes and genetic ablation of endothelial NO synthase (eNOS) in animal models. 36, 37 It is clinically important to estimate the degree of endothelial dysfunction. Several methods have been used to assess endothelial function in humans. However, unfortunately, there is no gold standard for assessing endothelial function. Recently, several investigators, including us, have evaluated the effects of intra-arterial infusion of NO agonists, such as acetylcholine, methacholine and bradykinin, and intra-arterial infusion of NO antagonists on forearm blood flow using a mercury-filled Silastic strain-gauge plethysmography and the effects on coronary blood flow using a Doppler flow guide wire. [9] [10] [11] 17, 26, 27, 35 The responses to intraarterial infusion of vasoactive agents should be most suitable for assessing endothelial function, because the use of agonists to stimulate NO release and the use of antagonists of NO allow us to draw more specific conclusions concerning the role of basal and stimulated NO release. However, the invasive methods are time consuming and are a burden for patients. A noninvasive method for measuring forearm blood flow response to reactive hyperemia would also be useful for assessing endothelial function. 38, 39 Measurement of flow-mediated vasodilation (FMD) in the brachial artery using ultrasound is noninvasive and reflects NO production very well. 40, 41 It is accepted that measurement of forearm blood flow responses to vasoactive agents and reactive hyperemia is an index of resistance artery endothelial function and that measurement of FMD is an index of conduit artery endothelial function. Recently, finger plethysmography peripheral arterial tonometry has also been used. 42, 43 Circulating levels of nitrite/nitrate, cyclic guanosine 3 0 ,5 0 -monophosphate, vascular cell adhesion molecule-1, intracellular adhesion molecule-1, monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, von Willebrand factor, asymmetrical dimethylarginine, endothelial microparticles and progenitor cells are also measured as indices of endothelial function. 21, [44] [45] [46] [47] However, these measurements do not directly reflect the production of NO from endothelial cells and are not 'function' . Measurement of circulating levels of NO metabolites, inflammatory markers and adhesion molecules should be used as an adjuvant to the measurement of forearm blood flow responses to vasoactive agents or FMD.
ENDOTHELIAL DYSFUNCTION AND AGING
Aging may alter the structure and function of vascular components, such as the endothelium, intimas and smooth muscle cells, resulting in an increase in the risk of development of cardiovascular and cerebrovascular diseases, which are related to hypertension. [3] [4] [5] In particular, aging-related endothelial dysfunction would contribute to pathogenesis, maintenance and development of atherosclerosis. Endothelial dysfunction is the initial step of atherosclerosis and is involved in the development of atherosclerosis. Attenuation of endothelium-dependent vasodilation has been observed in elderly subjects and animal models. 48, 49 Several possible mechanisms by which advancing age impairs endothelial function are postulated (Figure 2 ). An imbalance between NO and ROS, so-called 'oxidative stress,' should be a key regulator of age-induced endothelial dysfunction. Aging activates nicotinamideadenine dinucleotide phosphate (NADPH) oxidase, xantine oxidase, cyclooxygenase and mitochondrial electron transport and inactivates the antioxidant system, including superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase, leading to an increase in ROS production and decrease in ROS degradation. First, ROS directly inhibit NO activity. ROS activate the PI3K/Ras/Akt/MAPK pathway, related to redox transcriptional factors, leading to redox gene expression, which results in inhibition of eNOS mRNA expression and eNOS activity. Oxidation of tetrahydrobiopterin (BH 4 ) by ROS induces eNOS uncoupling, and eNOS uncoupling produces ROS rather than NO. 50 Under the condition of oxidative stress, BH 4 predominantly produces superoxide, leading to peroxinitrite. 51 Recently, the role of endothelial progenitor cells (EPCs) in endothelial function has been noted. Hill et al. 44 have shown that the number of EPCs is decreased in relation to the cumulative number of Framingham risk factors and that the number of EPCs is correlated with endothelial function measured by FMD. In the early stage of endothelial dysfunction, impaired endothelial cells should be repaired by bone-marrow-derived EPCs. Decrease in the number of EPCs in bone marrow or inhibition of EPC mobilization may contribute to progression of endothelial dysfunction. Werner et al. 52 reported that the cumulative event-free survival in analysis of a first major cardiovascular event at 12 months, according to levels of circulating EPCs at the time of enrollment in patients with cardiovascular disease. The cumulative event-free survival rate increased stepwise across three increasing baseline levels of EPCs in an analysis of death from cardiovascular causes. These finding suggest that the number of EPCs is a predictor of cardiovascular events. In addition, several investigators, including us, have shown a significant relationship between the member of EPCs and endothelial function in patients with cardiovascular diseases and even in normal subjects. 44, 45 In our study, the number of EPCs significantly correlated with the number of total risk factors. Multiple regression analysis showed that age and hypertension are independent predictors of the number of EPCs. 45 Experimental and clinical studies have clearly shown that excessive oxidative stress decreases the number of EPCs and impairs EPCs function. 53, 54 Under the condition of excessive oxidative stress, aging-associated decrease in NO bioavailability and decrease in the number of EPCs and EPC mobilization may form a vicious circle and contribute to endothelial dysfunction.
Finally, several lines of evidence have shown that eNOS activity and NO production are decreased in senescent endothelial cells. 55, 56 The process of endothelial cell senescence may have a critical role in endothelial dysfunction associated with aging ( Figure 3 ).
ENDOTHELIAL DYSFUNCTION AND HYPERTENSION
Several investigators have clearly shown that endothelial function is impaired in animal models of hypertension. 36 Systolic blood pressure was elevated by approximately 30 mm Hg in eNOS knockout mice compared with that in wild-type mice. 37 In hypertensive patients also, endothelium-dependent vascular relaxation in coronary, forearm and renal arteries was found to be impaired, and endothelial dysfunction, which is involved in the development of atherosclerosis, was found to increase the risk of cardiovascular and cerebrovascular diseases. [9] [10] [11] [12] [13] [14] [15] 27, 35 As Panza et al. 9 reported for the first time in 1990 that the dose-response curve obtained by acetylcholine in patients with hypertension was smaller than the curve in normal controls and that the dose-response curves obtained by sodium nitropreside were similar in the two groups, suggesting that endothelial function, but not smooth muscle function, is selectively impaired in patients with hypertension, a large number of studies have shown that hypertension is associated with endothelial dysfunction.
However, although various factors contribute to the impartment of endothelial function in hypertension, the precise mechanisms remain unclear. Initially, agonists bind to receptors and/or shear stress activates eNOS, and NO, which is produced by L-arginine in the presence of eNOS in the endothelium, activates cytosolic guanylate cyclase and increases cGMP content in vascular smooth muscle cells, resulting in relaxation of vascular tone. Thus, it seems reasonable to assume that there is a problem somewhere in this L-arginine-NO-cGMP pathway. Several investigators have reported possible mechanisms of impairment of endothelial function in hypertension: increase in amount of the endogenous eNOS inhibitor asymmetrical dimethylarginine, increases in amounts of vasoconstrictors, such as Ang II, endothelin-1 and norepinephrine, and inactivation of NO by ROS. 57 Several studies using animal models of hypertension and patients with hypertension have shown that endothelial dysfunction is associated with an increase in ROS. 58, 59 Amounts of antioxidant scavengers, such as SOD, GPx, catalase and vitamin C and E, are decreased in patients with hypertension. 60 NADPH oxidase, which is a major source of production of ROS in vessel walls, is activated in hypertensive rats. 61, 62 It has also been shown that ascorbic acid restores impaired endothelium-dependent vasodilation in patients with essential hypertension. 63 Therefore, enhanced production of ROS and an attenuated antioxidant system may contribute to endothelial dysfunction in patients with hypertension. Enhanced NO inactivation caused by excess ROS production, rather than decreased NO production, may have an important role in impairment of endothelium-dependent vasodilation. These findings suggest that a decrease in NO inactivation contributes to the improvement in endothelial dysfunction in patients with hypertension. In various pathophysiological states, including hypertension, xanthine oxidase, NADPH oxidase and uncoupled eNOS are likely enzymatic sources contributing to increased production of ROS. 64 An imbalance of decreased production of NO or increased production of ROS promotes endothelial dysfunction, leading to remodeling, platelet aggregation, loss of vasodilation, inflammation and smooth muscle cell growth.
Moreover, there is the question of whether endothelial dysfunction is a cause or consequence of hypertension. Several lines of evidence have suggested that endothelial function is impaired as blood pressure increases and that the degree of dysfunction is related to the magnitude of blood pressure elevation, 64, 65 indicating that endothelial dysfunction is a consequence of hypertension. In contrast, Taddei et al. 66 recently presented interesting results showing that young offspring of essential hypertensive patients who have a family history of hypertension are characterized by a reduced response to acetylcholine linked to a defect in the NO pathway, suggesting that endothelial dysfunction may be a cause of hypertension. There is still insufficient evidence for a conclusion to be reached.
OXIDATIVE STRESS
NADPH oxidase NADPH oxidase is the most important source of ROS in the vasculature. 67 NADPH oxidase is a multisubunit complex composed of cytosolic components, such as p47 phox , p67 phox and Rac 1, and membrane-spanning components, such as p22 phox and gp91 phox . The production of ROS by activated NADPH oxidase is mediated by several pathways. 59, 60, 68 Ang II-induced NADPH oxidase activation is one of the major sources of ROS in atherosclerosis. 18, 19, 67, 68 Zalba et al. 68 showed that endothelial dysfunction is due to an excess of ROS rather than a decrease in NO production in the aorta of spontaneously hypertensive rats and is associated with both upregulation of p22 phox mRNA expression and increased activity of NADPH oxidase. Upregulation of p22 phox mRNA expression is a key component of Ang II-induced NADPH oxidase activation, and increased expression levels of other components also have an important role in this oxidase under pathological conditions. 18 Increased mRNA expression levels of p47 phox , p67 phox , p22 phox and gp91 phox have been found in internal mammary arteries of patients with cardiovascular diseases and diabetes mellitus. Guzik et al. 19 reported that impairment of acetylcholine-induced vasodilation, increase in NADPH oxidase activity and NADPH oxidase-induced ROS generation in saphenous veins in patients with cardiovascular diseases are related to each other and are associated with increased risk of atherosclerosis. In addition, patients with renovascular hypertension are ideal models for determining how endotheliumdependent vasodilation is affected by excess Ang II and Ang II-related increase in oxidative stress. 17 Renal angioplasty decreased plasma renin activity, plasma Ang II concentration and serum malondialdehyde-modified low-density lipoprotein (MDA-LDL) concentration and urinary 8-hydroxy-2 0 -deoxyguanosine (8-OHdG) excretion, indices of oxidative stress, in patients with renovascular hypertension. After renal angioplasty, forearm blood flow response to acetylcholine was enhanced in patients with renovascular hypertension. Co-infusion of the antioxidant vitamin C augmented the forearm blood flow response to acetylcholine before angioplasty but not after angioplasty. The increase in maximal forearm blood flow response to acetylcholine correlated with the decrease in urinary excretion of 8-OHdG and the decrease in serum concentration of MDA-LDL. These findings suggest that endothelial function is impaired in relation to the severity of oxidative stress in humans.
SOD, GPx and catalase
Protective antioxidant mechanisms are complex and multifactorial. The antioxidant defense system, including SOD, GPx and catalase, Endothelial dysfunction eNOS Figure 3 Putative process of endothelial cell senescence with aging and putative process from endothelial cell senescence to endothelial dysfunction. eNOS, endothelial nitric oxide synthase; ROS indicates reactive oxygen species; TERT, telomerase reverse transcriptase.
Endothelial function and hypertension in aging
Y Higashi et al scavenges ROS in the vasculature, resulting in inhibition of NO degradation. The susceptibility of vascular cells to oxidative stress is a function of the overall balance between the degree of oxidative stress and the antioxidant defense capability. The antioxidant enzyme SOD rapidly dismutates superoxide to hydrogen peroxide. SOD has been identified as three enzymatic types: Cu/Zn SOD, Mn SOD and extracellular SOD. Destruction of the antioxidant system, including decreased antioxidant enzyme activity and ROS scavenging ability, may contribute to oxidative stress in patients with atherosclerosis. Indeed, circulating levels of SOD diminished in relation to aging. 69 Various interventions such as administration of antioxidant vitamins and antihypertensive agents and exercise training have been shown to enhance the protein levels and enzymatic activities of SODs, such as Cu/Zn SOD and Mn SOD, in the vascular endothelium and smooth muscle cells of the aorta in various animal models. 70, 71 In the vasculature of humans, approximately 50% of total SOD is extracellular SOD. 72 Fukai et al. 73 demonstrated that exercise for 3 weeks increased eNOS and extracellular SOD protein levels in wildtype mice but had no effect on extracellular SOD protein levels in eNOS-knockout mice and that the effect of endothelium-derived NO on extracellular SOD protein level is mediated by the cGMP/protein kinase G-dependent pathway. Taken together, impairment of the antioxidant defense system associated with aging and hypertension may contribute to endothelial dysfunction.
Tetrahydrobiopterin (BH 4 )
eNOS requires several cofactors, such as heme, flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), as well as BH 4 for elicitation of full enzymatic activity. 74,75 BH 4 is an allosteric factor in the coupling of the oxidase and reductase domains of eNOS. 50 Recently, it has been reported that a deficiency of BH 4 results in a decrease in NO synthesis and an increase in production of ROS. 51 Sowers 20 emphasized the role of BH4 in oxidative stress and endothelial function. In animals and humans of advanced age, dysfunctional eNOS with insufficient BH 4 induces production of ROS, resulting in a decrease in NO bioavailability. 75 Reduced availability of BH 4 may contribute to the development and maintenance of atherosclerosis. In addition, it has been demonstrated that supplementation of BH 4 or folic acid improves endothelial function in smokers, in patients with diabetes, hypertension, hypercholesterolemia and chronic heart failure and in elderly subjects. [76] [77] [78] [79] [80] [81] [82] Co-infusion of BH 4 resulted in a significant increase in acetylcholine-induced vasodilation in healthy men. 78 Aging was found to be significantly correlated with acetylcholineinduced vasodilation, urinary 8-OHdG, serum MDA-LDL and change in acetylcholine-induced vasodilation after co-infusion of BH 4 . Infusion of N G -monomethyl-L-arginine, an NO synthase inhibitor, abolished the BH 4 -induced enhancement of forearm vasorelaxation evoked by acetylcholine. Also in hypertension, a deficiency of BH 4 decreases NO synthesis and increases superoxide production, and reduced availability of BH 4 may contribute to the development and maintenance of hypertension. Indeed, during co-infusion of BH 4 , the forearm blood flow response to acetylcholine in hypertensive patients increased significantly to the level of normal controls. 78 After N G -monomethyl-L-arginine infusion, BH 4 -induced augmentation of endothelium-dependent vasodilation was completely abolished. These findings suggest that a deficiency of BH 4 may be involved in the pathogenesis of disturbances in endothelium-dependent vasodilation related to aging and hypertension through decrease in NO production and increase in oxidative stress.
Several lines of evidence have suggested that oxidative DNA damage is increased in relation to aging. 83, 84 Levels of aldehydes, such as MDA-LDL and 4-hydroxy-2-nonenal (4-HNE), have been proposed as a biological signature of clinical in vivo LDL oxidation. [85] [86] [87] [88] [89] Mutlu-Turkoglu et al. 87 reported that plasma MDA levels were increased in elderly subjects compared with those in young subjects. Lovell et al. 89 have shown that ventricular fluid levels of 4-HNE are significantly higher in patients with Alzheimer's disease, an agerelated disease, than in control subjects. We also confirmed that aging correlated with urinary 8-ODdG excretion and serum MDA-LDL concentration, suggesting that oxidative stress progressively increases with aging. 79 Several investigators have shown that both oxidized LDL and native LDL downregulate eNOS mRNA and protein levels in endothelial cells. 90, 91 Interestingly, 4-HNE mediated eNOS uncoupling and superoxide generation through alteration of BH 4 homeostasis in bovine aorta endothelial cells. 92 Therefore, although the effect of MDL-LDL on endothelial function in humans is not clear, MDA-LDL is not merely a marker of oxidative stress but also may directly impair endothelial function through a decrease in the expression of eNOS.
While eNOS activation at optimal levels of BH 4 leads to production of NO, activation of NOS in the absence of or in the presence of decreased levels of BH 4 results in generation of superoxide rather than NO in the vascular endothelium. 16, 17 Under conditions of BH 4 deficiency, electron flow from the reductase domain to the oxidase domain is diverted to molecular oxygen rather than to L-arginine, a substrate of NO, leading to eNOS uncoupling. In this condition, uncoupled eNOS produces superoxide rather than NO. 20 In aging models, dysfunctional eNOS with insufficient BH 4 causes superoxide generation, resulting in decreased NO bioaviliability. 75 It has recently been reported that degradation of BH 4 by ROS, including peroxynitrite, superoxide and hydrogen peroxide, is associated with downregulation of eNOS. 93 These findings suggest that BH 4 deficiency and decreased eNOS activity cause endothelial dysfunction in elderly subjects and in patients with hypertension through an increase in oxidative stress. Therefore, BH 4 supplementation may increase the intracellular content of BH 4 and augment acetylcholine-induced vasodilation by inhibition of NO inactivation.
RhoA/Rho-associated kinase (ROCK) Recent studies have shown that the ROCK family, one of the several small GTPase Rho effectors, has major roles in actin cytoskeleton organization, 94 smooth muscle contraction 95 and gene expression. 96 Results of previous studies have shown that ROCK has a role in the contraction of vascular smooth muscle cells. ROCK activates myosin light-chain kinase by phosphorylation of the myosin-binding subunit in myosin light-chain phosphatase, leading to contraction of vascular smooth muscle cells. 97, 98 Indeed, the RhoA/ROCK pathway has been shown to be involved in the formation of atherosclerotic lesions, vasoconstriction and myocardial hypertrophy and to be activated in patients with hypertension and in patients with coronary artery disease. [99] [100] [101] [102] [103] [104] Recently, we have shown that FMD is an independent predictor of leukocyte ROCK activity in healthy men and men with cardiovascular risk factors but without established cardiovascular or cerebrovascular diseases, suggesting that cumulative cardiovascular risk, including aging and hypertension, may enhance ROCK activity and endothelial dysfunction. 105 Activation of the RhoA/ROCK pathway impairs NO bioavailability through inhibition of eNOS mRNA stability, eNOS posphorylation at Ser 1177 and the Akt/PI3K pathway and enhancement of eNOS phosphorylation at Thr495. [106] [107] [108] Endothelial function and hypertension in aging Y Higashi et al Several investigators have shown an interaction between the RhoA/ ROCk pathway and ROS. 109, 110 Indeed, ROS induced by hyperglycemia enhances ROCK activity, leading to atherothrombogenesis through an increase in expression of plasminogen activator inhibitor-1 in vascular endothelial cells. 111 It is well known that cigarette smoking decreases NO bioavailability through the production of ROS. Several investigators, including us, have demonstrated that there is a possible association of ROCK activity with oxidative stress and that smoking enhances the activation of ROCKs in vascular smooth muscle cells in vivo and in vitro. 98, 109, 112 These findings suggest a correlation between oxidative stress and ROCK activity in humans. Hernandez-Perera et al. 113 showed that Rho is required for the basal expression of preproendothelin-1 in vascular endothelial cells, which gives rise to endothelin-1. On the other hand, several investigators have shown that NO blocks the migration of RhoA from the cytosol to the membrane, thereby inhibiting the RhoA/ROCK signaling pathway. 114, 115 It is thought that there is an interaction between activated ROCK and endothelial dysfunction in human vessels. Indeed, we have confirmed that hypertension is associated with both endothelial dysfunction and increased ROCK activity, and that endothelial dysfunction and increased ROCK activity are simultaneously improved by an aldosterone blocker in patients with hypertension. These findings indicate close interactions between ROCK activity, endogenous NO and oxidative stress.
Interestingly, ROCK activity was significantly correlated with systolic blood pressure even in healthy young male subjects with normal blood pressure. 116 This finding is supported by results of previous studies showing that ROCKs are involved in the pathogenesis of hypertension through, at least in part, causing vascular smooth muscle cell contraction. [117] [118] [119] There is a possibility that ROCK activity regulates blood pressure from the normal range to high levels.
ENDOTHELIAL CELL SENESCENCE
If endothelial cells are altered to senescence, structural and functional changes in endothelial cells, including alteration in gene expression occurs in relation to the advancing cell senescence. Telomeres are located at the ends of the chromosome to protect DNA damage signals and to diminish the activation of DNA repair in various types of cells, including endothelial cells. 120, 121 Activity of telomerase, a catalytic subunit telomerase reverse transcriptase (TERT), regulates the DNA length of telomeres. 122, 123 Therefore, telomere length and activity of telomerase, especially TERT, have a critical role in endothelial cell senescence. It is well known that aging and hypertension are associated with shortening of telomeres induced by decrease in TERT activity in endothelial cells. [124] [125] [126] However, unfortunately, it remains unclear whether telomere shortening is a cause or consequence of aging.
Endothelial cell senescence per se can cause endothelial dysfunction. Several lines of evidence have shown that telomere length in endothelial cells from human aortas and arteries shortens in relation to aging. 127, 128 Decreases in both NO production and eNOS activity in human umbilical vein endothelial cells and human aortic endothelial cells (HAECs) are associated with aging. 129, 130 Matsushita et al. 130 demonstrated that shear stress-induced increase in NO production was diminished in senescent HAECs and that stable expression of TERT restored the decreased eNOS expression and NO production associated with aging. Minamino et al. 131 reported that HAECs from human atherosclerotic lesions presented phenotypes of senescent cells and decreases in eNOS expression and eNOS activity.
Introduction of TERT extended the life span and restored endothelial functional alteration associated with senescence in HAECs. Interestingly, exogenous NO reduced human umbilical vein endothelial cell senescence and delayed age-dependent inhibition of telomerase activity, suggesting that telomerase inactivation precedes endothelial cell senescence and that NO prevents age-related downregulation of telomerase activity and delays endothelial cell senescence. 132 Nakashima et al. 133 showed by measuring the mean telomere restriction fragment length that telomere lengths in white blood cells shorten in parallel to a decline in endothelial function by FMD in patients with various degrees of cardiovascular damage as well as in healthy subjects.
The process of endothelial dysfunction associated with aging in relation to endothelial cell senescence is postulated as follows (Figure 3 ): Aging and hypertension activate NADPH oxidase, xantine oxidase, cyclooxygenase and mitochondrial electron transport and inactivate the antioxidant system, leading to increase in ROS production and decrease in ROS degradation. ROS induce export of nuclear TERT into the cytosol through activation of Src-family kinases. 134, 135 Inhibition of nuclear TERT activity shortens telomere length, leading to decrease in the endothelial cell's life span, alteration in gene expression and change from phenotype of young cells to phenotype of old cells. 136 In addition, telomere shortening stimulates activation of p53, p21 and p16 proteins, which are triggers of cell senescence. 137, 138 The endogenous eNOS inhibitor asymmetrical dimethylarginine also accelerates endothelial cell senescence through increase in production of ROS and inhibition of NO production. 139 An imbalance between NO and ROS may be the initial step of endothelial cell senescence and may have an important role in endothelial cell senescence. Endothelial cell senescence results in endothelial dysfunction through various pathways.
CONCLUSIONS
Reduced NO bioavailability and reduced number and function of EPCs by ROS and endothelial cell senescence may contribute to endothelial dysfunction in aging. In hypertension also, similar mechanisms may work in the process of endothelial dysfunction. Aging, aging-associated hypertension and hypertension per se, either independently or collectively, impair endothelial function, leading to atherosclerosis, resulting in cardiovascular and cerebrovascular outcomes. It is expected that improvement or augmentation of endothelial function will prevent the development of atherosclerosis, resulting in reduction in cardiovascular and cerebrovascular events. Intervention to reduce oxidative stress should be an effective strategy for treatment of atherosclerosis, including aging and hypertension, through, at least in part, improvement in endothelial function and endothelial cell senescence. 
